The Economical Solution for increased poductivity when tansferring between sample formats Anachem is pleased to introduce a world's first, with the new RAININ Multi-Lite Adjustable Spacer Pipette. Ideal for routine micro-well applications, this totally unique pipette allows you to quickly and accurately change nozzle spacing for use with different storage formats. Transfer your samples with the greatest of ease between micro centrifuge tubes, 24, 48 and 96-well plates - just a twist is all it requires to change spacing. Previously, such functionality has only been available on more expensive electronic pipettes.

Now available from Anachem, the New 4titude® PlateStable™ system provides fully automated sample storage that maintains high quality compound libraries safely and effectively. PlateStable protects the integrity of solid and liquid samples by controlling the internal environment within its sealed, contaminant free enclosures. PlateStable contains one control module and a flexible number of containers that house SBS standard laboratory plates or tube racks. Different models offering a range of sizes and capacity accommodate individual requirements. The system is easy to use and operates simply by loading plates or tube racks into the enclosure, which is then sealed and connected to a control unit producing a short cycle that flushes out the existing oxygen atmosphere and replaces it with dry gas such as Nitrogen or Argon.

The results of the landmark ONTARGET Trial have proven that telmisartan, brand name MICARDIS, a modern Angiotensin II Receptor Blocker (ARB), is as protective as the current gold standard, ramipril, in reducing the risk of cardiovascular death, myocardial infarction, stroke, and hospitalisation for congestive heart failure in a broad cross-section of high-risk cardiovascular patients and with better tolerability. These cardiovascular events occurred in 16.66% of patients receiving telmisartan versus 16.46% of patients receiving ramipril. The relative risk (ratio of the probability of the event occurring in the telmisartan group versus the ramipril group) was 1.

Boehringer Ingelheim enjoyed continued success through 2007, its growth outpacing the pharmaceuticals market for the eighth time in succession. As the Company announced at its annual press conference in Ingelheim, turnover rose by +8.8% in local currency (+3.6% in euro terms) to almost &uro;11 billion (2006: &uro;10.5 billion). At &uro;2.1 billion, operating income - comparable to the EBIT - is at the previous year's level. This corresponds to an operative margin (ratio of operating income to net sales) of 19.2%. Income after tax was a good &uro;1.8 billion, signifying an increase of +4.8% over the previous year.

DSM Nutritional Products announces a global price increase for all fat soluble vitamins. After recent price increases announced for Vitamin E and A the remaining fat soluble vitamins in the portfolio - K1, Natural Source Vitamin E, Mixed Tocopherols and Vitamin D3- will now also increase in price for all newly contracted business.

The increase is effective for all qualities of these vitamins marketed in the human nutrition and personal care industries and will amount to a minimum of 10%.

The price increase is necessary due to significantly higher costs of raw materials, energy and transportation and due to higher demand for DSM quality vitamins.

Schenck Process is the best example of the successes a good strategy process can deliver. In recognition of the successful definition and ongoing realisation of its growth strategy, the Schenck Process Group are delighted to announce that management consults Oliver Wyman and the Produktion business journal have conferred their 2007 Strategy Award for Mechanical Engineering Companies in the category of 'Best Growth Strategy' on the Schenck Process Group. Citing ability to achieve targeted financial results, in presenting the award Oliver Wyman acknowledges Schenck Process' transition from a component supplier to a leading provider of complete solutions.

Simple product navigation on new Anachem website Anachem's new enhanced website has been dramatically re-developed to provide a faster and more effective tool that enables customers to find products they need at the click of a button. The highly advanced search facilities have been greatly refined to allow users to filter through the cleverly structured product catalogue or search by keyword, whole or partial part number to quickly locate specific product information. The homepage presents a comprehensive list of categories that defines the product type and application area. These are also represented by horizontal page tabs directing users to the required product catalogue areas.

Unigene Laboratories has successfully completed the Phase I/II oral calcitonin clinical study that it initiated last month. This study, which achieved all of its planned objectives, primarily measured the ability of Unigene's proprietary oral delivery technology to significantly reduce the levels of an established biochemical marker that correlates with bone loss. All of the twenty-two subjects who completed the study demonstrated a robust reduction in this marker. In addition, the study demonstrated a dose-dependent increase in calcitonin blood levels. This is the second successful clinical study that the company has conducted using its improved oral calcitonin formulation.

Unigene Laboratories reported that the results of animal studies confirming the ability of its novel technology to rapidly form and maintain natural bone growth at targeted locations has been published. The paper, entitled "Replacement of Bone Marrow by Bone in Rat Femurs: The Bone Bioreactor," summarizes the early-stage collaborative work performed by researchers at Yale University School of Medicine and Unigene, and appears in the most recent edition of the journal Tissue Engineering. The paper evaluated the effect of bone marrow removal from targeted sites followed by different schedules of daily injections of anabolic agents such as parathyroid hormone (PTH).

Unigene Laboratories announced plans to broaden the activities of its joint venture with the Shijiazhuang Pharmaceutical Group ("SPG") and to expand the potential product line to be developed and marketed by the joint venture. Unigene and SPG plan to establish the SPG-Unigene Biotechnology Research Institute in China. The Institute will continue ongoing registration activities for Unigene's calcitonin products, develop biopharmaceutical manufacturing facilities compliant with US current Good Manufacturing Practice guidelines, and establish and supervise the creation of a new pharmaceutical distribution network for joint venture products in China, all to take advantage of the world's largest osteoporosis market.

Osteoporosis - a skeletal disease that traditionally affects those age fifty and older - is a major public health problem. New guidelines released by the National Osteoporosis Foundation (NOF) call for bone mineral density (BMD) testing for all men ages seventy and older and for younger men with risk factors for bone loss. BMD testing is also urged for women sixty-five and older, and postmenopausal women that have risk factors for bone loss. "These guidelines represent the newest advances healthcare professionals can use to identify and treat patients with low bone mass, risk of fracture, or osteoporosis," says noted expert Dr.

Unigene Laboratories reports that a comparative analysis of various osteoporosis therapies has been published, concluding that there is insufficient evidence to support claims of superior effectiveness among the drugs reviewed. The study, commissioned by the Agency for Healthcare Research and Quality, Department of Health and Human Services, is entitled The Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis. The study was performed by the Southern California/RAND Evidence-based Practice Center to assist physicians, patients, private- and public-sector organizations in making informed decisions about pharmaceutical alternatives for osteoporosis and reviewed data for bisphosphonates, calcitonin, parathyroid hormone, estrogen, selective estrogen receptor modulators and testosterone.

The ScreenTape system, developed by Lab90 and distributed by Anachem, employs a unique microscale polymer tape that contains all the reagents required for DNA electrophoresis. It brings major advantages of convenience, ease of use and safety to molecular biologists as absolutely no handling of gels and buffers is required. The compact, fully automated ScreenTape instrument replaces the need for hand-cast gels, buffers, gel tanks and gel-doc systems. In just under ten minutes the system loads the samples, runs the gel, images and presents the fully analysed results (including gel picture, band sizes and quantitative data).

Which feeder is best for which bulk material? In order to provide customers with accurate answers to this question, Schenck Process are now offering tests at their new, modern TestCenter in Darmstadt that are based on real life situations. The specialist in measuring and process technologies invited its customers to the centre's official opening on 27 February. More than 100 people attended the event to learn more about what the new centre has to offer. Just like at a trade fair, the event enabled them to view several highlights under one roof. More test rigs and an improved level of automation mean that the TestCenter can now run even more accurate tests, all very closely based on actual processing circumstances.

Vaisala has introduced a new generation Vaisala HUMICAP® relative humidity sensor, the Vaisala HUMICAP 180R used in Vaisala industrial humidity transmitters. This new type of capacitive humidity sensor has been developed especially to cope with chemical interference. In most humidity measurement applications, the sensors are also exposed to chemicals other than water vapor. Such vapors are present in most environments, even in normal office air. As the responses to some gases and vapors are very slow, in many cases several weeks or months, the effects are often described as 'drift' or 'aging' of the sensor and not as chemical interference.

Pharmagel Engineering develops Softgel Technology for pharmaceutical, nutraceutical and cosmetic products. SOFTGEL The softgel (soft gelatine) capsule is a one piece, hermetically sealed shell wall filled with oils and non-acqueos liquids, plus solids in a paste or solution form. The shell gives a unique strength and durability to softgels, and in addition protects the inner fill material from atmospheric oxidation that compromises other oral dosage forms in terms of potency and shelf life. Softgel has become widely used in prescription and OTC pharmaceuticals, plus also in nutraceuticals, because of the following advantages: Improved bioavailability Easier to swallow Better consumer confidence Elegant appearance Masks odours Longer shelf life Rapid action Easy and flexible formulation WHO ARE PHARMAGEL Pharmagel is the leading supplier of semi-turnkey softgel encapsulation plants worldwide, having been engaged in the research and development of encapsulation lines and the formulation of softgels for 4 decades.

Unigene is a biopharmaceutical company that delivers oral and nasal delivered peptide drugs for the global osteoporosis market. Our major products include nasal / oral salmon calcitonin - oral PTH analogs, oral glucose regulatory peptides, oral leuprolide, oral desmopressin and oral PYY(3-36) NH2. The company's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support our worldwide commercialization strategy of oral and nasal therapeutics. Unigene's R&D work focuses on a range of pharmaceutical products and procedures including recombinant DNA technology, analytical and immunoassay test development, protein chemistry and more.

QED Scientific was established in 1997 to supply incubators, ovens and refrigeration equipment for the UK healthcare market. Since then the company has steadily expanded, firstly to include equipment for pathology and operating theatres and then to supply environmental chambers for industry and pharmaceutical quality-control laboratories. More recently QED Scientific has been supplying cabinets and enclosures that use carbon filters to control undesirable odours and these include everything from DNA fingerprint cabinets to standard bench fume hoods. We also offer site validation and mapping for all cabinets, both new and those already in your laboratory.

Genentech Inc is one of the leading biotechnology corporations in the US, founded in 1976 with its HQ in San Francisco Bay in South San Francisco, California. The company is regarded by many as one of the pioneers of the biotech industry. Genentech now has facilities all around the world and employs more than 10,000 personnel. "Genentech now has facilities all around the world and employs more than 10,000 personnel." The majority shareholder of Genentech Inc is the Swiss pharmaceutical company Hoffmann La Roche. The company has many products in the commercial market in most spheres of treatment, including Activase/Cathflo, Nutropin, Pulmozyme, Rituxan, Herceptin, TNKase, Xolair, Raptiva, Avastin, Tarceva and Lucentis.

Pfizer Manufacturing Deutschland GmbH is a large secondary manufacturing centre for Pfizer in Germany and has a reputation for efficiency, high containment and economy. The facility in Illertissen needed to increase its capacity in early 2006 to accommodate the growing market demand for the newly developed smoking cessation drug Chantix. The drug was first released to the commercial market in 2006 and Pfizer at Illertissen was the secondary production plant chosen to produce the drug from the highly potent API varenicline, which is produced in Ireland at the Little Island plant. "The NEWCON facility was conceived, planned and constructed in a short timescale between 2006 and 2008.

Bristol-Myers Squibb (BMS) has been undergoing much the same rationalisation process as many large pharmaceutical companies have during the last couple of years. "This expansion will form the basis of clinical supplies manufacture and drug product technology development." The pharmaceutical development business is changing and with these changes BMS has introduced a new strategy for the discovery of innovative medicines in areas of unmet medical need, in major areas such as Alzheimer's, diabetes, arthrosclerosis, hepatitis, AIDS/HIV, oncology and arthritis. In order to further develop its product pipeline and to develop collaboration and produce clinical supplies for trials, BMS has set up a new Center of Excellence at its New Brunswick, New Jersey facility in the US.